JNJ-63623872
Sponsors
Janssen Cilag N.V./S.A., Janssen Research & Development, LLC, Janssen-Cilag International NV, Alios Biopharma Inc.
Conditions
HealthyInfluenza A VirusInfluenza in Humans
Phase 1
Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants
CompletedNCT02448004
Start: 2015-05-11End: 2015-06-24Updated: 2017-07-02
A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants
CompletedNCT02595268
Start: 2015-11-30End: 2016-01-31Updated: 2016-01-27
A Study to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone
CompletedNCT02652650
Start: 2015-12-31End: 2016-06-30Updated: 2016-06-06
A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants
CompletedNCT02658825
Start: 2016-01-31End: 2016-04-30Updated: 2025-02-03
Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults
CompletedNCT02860806
Start: 2016-08-08End: 2017-06-10Updated: 2018-01-30
A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872
CompletedNCT02888327
Start: 2016-07-31End: 2017-05-30Updated: 2025-02-03
A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult Participants
CompletedNCT03023852
Start: 2017-02-14End: 2017-04-14Updated: 2017-05-25